Format

Send to

Choose Destination
J Rheumatol. 2019 Feb 1. pii: jrheum.180784. doi: 10.3899/jrheum.180784. [Epub ahead of print]

Vaccination Guidelines for Patients with Immune-mediated Disorders Taking Immunosuppressive Therapies: Executive Summary.

Author information

1
From K. Papp Clinical Research; Probity Medical Research, Waterloo; University Health Network; Faculty of Medicine, University of Toronto; Mount Sinai Hospital, Toronto; Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton; Faculty of Medicine, Queen's University, Kingston; Faculty of Medicine, University of Western Ontario; St. Joseph's Health Care, London, Ontario; Centre Hospitalier de l'Université de Montréal; Innovaderm Research Inc.; McGill University Health Centre; Research Institute - McGill University Health Centre, Montreal, Quebec; Faculty of Medicine, University of British Columbia; St. Paul's Hospital; Vancouver Coastal Health; Vancouver General Hospital, Vancouver, British Columbia, Canada. Development of the vaccination guidelines was funded by the Dermatology Association of Ontario. The authors received no financial support for the research, authorship, and/or publication of this article. K. Papp is an advisory board participant, steering committee member, investigator, speaker, and/or consultant for AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Eli Lilly, Janssen, Merck (MSD), Novartis, and Valeant/Bausch Health. D. Kumar is an investigator for GSK, Oxford Immunotec, and Qiagen. J.K. Marshall is an advisory board participant, speaker, and/or consultant for AbbVie, Janssen, Pfizer, and Takeda. R. Bissonnette is an advisory board participant, investigator, speaker, and/or consultant for AbbVie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, Incyte, Janssen, and Pfizer, and is a shareholder of Innovaderm Research. A. Bitton is an advisory board participant, speaker, and/or investigator for AbbVie and Janssen. B. Bressler is an advisor and/or speaker for AbbVie, Allergan, Genentech, Janssen, Pfizer, and Takeda. M. Gooderham is an advisory board participant, investigator, consultant, and/or speaker for AbbVie, Amgen, Celgene, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Genzyme, and Valeant Pharmaceuticals. S. Jamal is a consultant for BMS, Eli Lilly, and UCB, and has received research grants from Merck, AbbVie, and BMS. A.H. Steinhart is an advisory board participant, speaker, investigator, and/or consultant for AbbVie, Amgen, Arena Pharmaceuticals, Celgene, Ferring, Genentech, Hoffmann-La Roche, Hospira, Janssen, Merck, Pfizer, Pharmascience, Red Hill Biopharma, and Takeda. D.C. Vinh is an advisory board participant, speaker, consultant, and/or investigator for Avir Pharma, Cidara, CSL Behring Canada, Novartis Canada, and Shire Canada. J. Wade is an advisory board participant and consultant for AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Roche, Sanofi, and UCB. K.A. Papp, MD, PhD, FRCPC, K. Papp Clinical Research, and Probity Medical Research; B. Haraoui, MD, FRCPC, Centre Hospitalier de l'Université de Montréal; D. Kumar, MD, MSc, FRCPC, University Health Network, and Faculty of Medicine, University of Toronto; J.K. Marshall, MD, MSc, FRCPC, AGAF, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University; R. Bissonnette, MD, Innovaderm Research Inc.; A. Bitton, MD, FRCP, McGill University Health Centre; B. Bressler, MD, MS, FRCPC, Faculty of Medicine, University of British Columbia, and St. Paul's Hospital; M. Gooderham, MSc, MD, FRCPC, Probity Medical Research, and Faculty of Medicine, Queen's University; V. Ho, MD, FRCPC, Faculty of Medicine, University of British Columbia; S. Jamal, MD, FRCPC, MSc, Vancouver Coastal Health; J.E. Pope, MD, MPH, FRCPC, Faculty of Medicine, University of Western Ontario, and St. Joseph's Health Care; A.H. Steinhart, MD, FRCP(C), Faculty of Medicine, University of Toronto, and Mount Sinai Hospital; D.C. Vinh, MD, McGill University Health Centre, and Research Institute - McGill University Health Centre; J. Wade, MD, FRCP(C), Faculty of Medicine, University of British Columbia, and Vancouver General Hospital. Address correspondence to Dr. K.A. Papp, K. Papp Clinical Research and Probity Medical Research, 135 & 139 Union St. East, Waterloo, Ontario N2J 1C4, Canada. E-mail: kapapp@probitymedical.com. Full Release Article. For details, see Reprints and Permissions at jrheum.org. Accepted for publication October 30, 2018.

Abstract

The use of immunosuppressive therapies for immune-mediated disease is associated with an elevated risk of infections and related comorbidities. While many infectious diseases can generally be prevented by vaccines, immunization rates in this specific patient population remain suboptimal, due in part to uncertainty about their efficacy or safety under these clinical situations. To address this concern, a multidisciplinary group of Canadian physicians with expertise in dermatology, gastroenterology, infectious diseases, and rheumatology developed evidence-based clinical guidelines on vaccinations featuring 13 statements that are aimed at reducing the risk of preventable infections in individuals exposed to immunosuppressive and immunomodulatory agents.

PMID:
30709945
DOI:
10.3899/jrheum.180784
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center